0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > MMP-9

MMP-9

Brief Information

Name:Matrix metalloproteinase 9
Target Synonym:EC:3.4.24.35,EC 3.4.24,CLG4B,MMP9,Matrix Metallopeptidase 9,Matrix Metalloproteinase 9 (Gelatinase B, 92kDa Gelatinase, 92kDa Type IV Collagenase),GELB,Matrix Metalloproteinase-9,92 KDa Type IV Collagenase,Macrophage Gelatinase,Type V Collagenase,Gelatina
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
MM9-H5221 Human Human MMP-9 Protein, His Tag (active enzyme)
MM9-H5221-structure
MM9-H5221-sds

Synonym Name

MMP9,CLG4B,GELB,MANDP2,Gelatinase B

Background

Matrix metallopeptidase 9 (MMP-9) is also known as 92 kDa type IV collagenase, 92 kDa gelatinase or gelatinase B (GELB), CLG4B, is secreted from neutrophils, macrophages, and a number of transformed cells, and is the most complex family member in terms of domain structure and regulation of its activity. . Structurally, MMP9 maybe be divided into five distinct domains: a prodomain which is cleaved upon activation, a gelatinbinding domain consisting of three contiguous fibronectin type II units, a catalytic domain containing the zinc binding site, a prolinerich linker region, and a carboxyl terminal hemopexinlike domain. This enzyme degrades various substrates including gelatin, collagen types IV and V, and elastin. MMP9 is involved in a variety of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, and be regarded as a potential therapeutic target.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CALY-001 CALY-001 Clinical Calypso Biotech Inflammatory Bowel Diseases; Crohn Disease Details
AQU-005 AQU-005; NMAQU-005; NM-AQU-005 Phase 1 Clinical Aquilus Pharmaceuticals Neuralgia Details
DP-b99 DP-b99; DP-Bapta-99 Phase 2 Clinical D-Pharm Brain Ischemia; Pancreatitis; Cerebrovascular Disorders; Stroke Details

This web search service is supported by Google Inc.

totop